Invention Publication
- Patent Title: BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
-
Application No.: US17804696Application Date: 2022-05-31
-
Publication No.: US20240058450A1Publication Date: 2024-02-22
- Inventor: Scott L. Ackler , Nathan B. Bennett , Erwin R. Boghaert , Steve C. Cullen , George Doherty , Robin R. Frey , Anthony R. Haight , Andrew S. Judd , Aaron R. Kunzer , Violeta L. Marin , Xiaoqiang Shen , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Xilu Wang , Dennie S. Welch , Michael D. Wendt
- Applicant: AbbVie Inc.
- Applicant Address: US IL North Chicago
- Assignee: AbbVie Inc.
- Current Assignee: AbbVie Inc.
- Current Assignee Address: US IL North Chicago
- Main IPC: A61K45/06
- IPC: A61K45/06 ; C07D417/14 ; C07D513/04 ; A61K47/68 ; A61K31/4709 ; A61K31/4725 ; A61K31/498 ; A61K31/4985 ; A61K31/538 ; C07D487/04
Abstract:
The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
Information query
